1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,117 | 0,136 | 16:11 | |
| 0,117 | 0,136 | 16:11 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | BRII-B (02137): VOLUNTARY ANNOUNCEMENT BUSINESS UPDATE | 1 | HKEx | ||
| 25.10. | BRII-B (02137): CANCELLATION OF SHARE OPTIONS AND RESTRICTED SHARE UNITS AND GRANT OF SHARE OPTIONS AND RESTRICTED SHARE UNITS | 1 | HKEx | ||
| 19.09. | BRII-B (02137): NOTIFICATION LETTER AND REQUEST FORM FOR NON-REGISTERED SHAREHOLDERS | - | HKEx | ||
| 19.09. | BRII-B (02137): NOTIFICATION LETTER AND CHANGE REQUEST FORM FOR REGISTERED SHAREHOLDERS | - | HKEx | ||
| 19.09. | BRII-B (02137): 2024 INTERIM REPORT | - | HKEx | ||
| 17.09. | BRII-B (02137): NEXT DAY DISCLOSURE RETURN | 1 | HKEx | ||
| 28.08. | BRII-B (02137): NEXT DAY DISCLOSURE RETURN (REVISED) | 1 | HKEx | ||
| BRII BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
| 27.08. | BRII-B (02137): NEXT DAY DISCLOSURE RETURN | 1 | HKEx | ||
| 19.08. | BRII-B (02137): INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2024 | 1 | HKEx | ||
| 05.08. | BRII-B (02137): DATE OF BOARD MEETING | - | HKEx | ||
| 31.07. | BRII-B (02137): VOLUNTARY ANNOUNCEMENT BUSINESS UPDATE | 1 | HKEx | ||
| 15.07. | BRII-B (02137): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | 1 | HKEx | ||
| 25.06. | BRII-B (02137): POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON JUNE 25, 2024, EXPIRATION OF TERM OF A NON-EXECUTIVE DIRECTOR AND APPOINTMENT OF A ... | 1 | HKEx | ||
| 07.06. | Brii Biosciences Limited: Brii Bio Presents New Data from Its Ongoing Phase 2 Chronic Hepatitis B Trials at EASL Congress 2024 | 389 | PR Newswire | New translational data demonstrate that BRII-179-induced immune responses are associated with high HBsAg reduction in a subset of participants with chronic HBV infection
BRII-179 as add-on therapy... ► Artikel lesen | |
| 07.06. | BRII-B (02137): VOLUNTARY ANNOUNCEMENT BUSINESS UPDATE | - | HKEx | ||
| 14.05. | Brii Biosciences Limited: Brii Biosciences Announces Two Breakthrough Therapy Designations for BRII-877 and BRII-835 Building on Extensive Clinical Evidence from Multiple Phase 2 Studies | 100 | PR Newswire | DURHAM, N.C. and BEIJING, May 13, 2024 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio " or the "Company", stock code: 2137.HK), a biotechnology company developing therapies to improve patient... ► Artikel lesen | |
| 22.03. | Brii Biosciences Limited: Brii Biosciences Provides Corporate Update and Reports Full-Year 2023 Financial Results | 387 | PR Newswire | Transitioning HBV cure programs into multiple late-stage combination studies with interim results throughout 2024 and 2025 informing Company's registrational strategyIntegrating R&D, manufacturing... ► Artikel lesen | |
| 14.02. | Brii Biosciences Limited: Brii Biosciences Announces Agreement to Acquire VBI's IP Rights in BRII-179 (VBI-2601) and Plans to Initiate Technology Transfer to Expand Clinical and Commercial Supplies | 177 | PR Newswire | Acquiring all intellectual properties relating to BRII-179 and eliminating future milestone and royalty payments to VBI, subject to achievement of certain activities
Transferring manufacturing technologies... ► Artikel lesen |
18 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIOGEN | 147,80 | -0,14 % | UCB And Biogen: Dapirolizumab Pegol Meets Primary Endpoint In Phase 3 PHOENYCS GO Study | WESTON (dpa-AFX) - UCB and Biogen Inc. (BIIB) presented detailed results from the Phase 3 PHOENYCS GO study evaluating dapirolizumab pegol, a Fc-free anti-CD40L drug candidate, showing significant... ► Artikel lesen | |
| ILLUMINA | 124,48 | -0,38 % | Aktie von Illumina kaum gefragt: Kurs bricht um 5,35 Prozent ein (127,8416 €) | Am US-amerikanischen Aktienmarkt fällt derzeit die Illumina-Aktie negativ auf. Das Papier verliert deutlich an Wert. Das Wertpapier von Illumina gehört heute mit einem Abschlag von 5,35 Prozent zu den... ► Artikel lesen | |
| NANOREPRO | 1,600 | +3,90 % | NanoRepro Aktie: Alles im Blick? | Die NanoRepro AG, ein führender Entwickler medizinischer Selbsttests, zeigt sich trotz wirtschaftlicher Herausforderungen widerstandsfähig. Am 09. November 2024 notierte die Aktie bei 1,64 EUR, unverändert... ► Artikel lesen | |
| BRAIN BIOTECH | 3,220 | +0,94 % | Brain Biotech, DAX, Erste Group, Fielmann, Microsoft, TUI - 4investors Aktien Top-News | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
| INFLARX | 1,916 | -1,49 % | InflaRx N.V.: InflaRx Receives Positive CHMP Opinion for GOHIBIC (Vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome | JENA, Germany, Nov. 15, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced... ► Artikel lesen | |
| BIONXT SOLUTIONS | 0,161 | -2,73 % | Trendwendesignal - Evotec, BioNxt Solutions, Moderna | "Ohne Investition keine Innovation und ohne Innovation kein Fortschritt" sollte das Motto in allen Wirtschaftszweigen der Welt sein. Ob im Maschinenbau, im Automobilbau, der Elektrotechnik wie auch... ► Artikel lesen | |
| SIRONA BIOCHEM | 0,048 | +2,13 % | Sirona Biochem meldet Veröffentlichung einer bahnbrechenden Studie zu Wirkstoff TFC-1326 im Journal of Cosmetic Dermatology | Vancouver, Kanada - 20. November 2024 / IRW-Press / Sirona Biochem Corp. (TSX-V: SBM) (FWB: ZSB) ist
stolz, die Veröffentlichung eines wichtigen Forschungsartikels im renommierten Journal of... ► Artikel lesen | |
| TREVENA | 0,153 | 0,00 % | Trevena Inc.: Trevena Reports Third Quarter 2024 Results and Provides Business Update | CHESTERBROOK, Pa., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,384 | +3,78 % | Defence Therapeutics Inc.: Defence Therapeutics Announces Securities for Debenture Financing | Vancouver, British Columbia--(Newsfile Corp. - November 14, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company... ► Artikel lesen | |
| BURCON NUTRASCIENCE | 0,094 | -9,13 % | Burcon NutraScience Corporation: Burcon Forms Alliance with Strategic Investor Group to Acquire Protein Production Facility | Vancouver, British Columbia--(Newsfile Corp. - November 20, 2024) - Burcon NutraScience Corporation (TSX: BU) (OTCQB: BRCNF) ("Burcon" or the "Company"), a global technology leader in the development... ► Artikel lesen | |
| CYTODYN | 0,126 | 0,00 % | CytoDyn Inc.: CytoDyn Announces FDA Clearance of Its Phase II Oncology Trial | VANCOUVER, Washington, Nov. 04, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential... ► Artikel lesen | |
| TME PHARMA | 0,137 | +5,07 % | TME Pharma N.V.: TME Pharma Awarded €2.4 Million German Federal Grant to Support NOX-A12 Phase 2 Trial in Brain Cancer | The grant program run by the German Federal Ministry of Education and Research (BMBF) supports SMEs working on innovative projects in biomedicine Non-dilutive support for planned phase... ► Artikel lesen | |
| IMMUNIC | 1,016 | +0,59 % | EQS-News: Immunic AG: Immunic Announces Publication of Data From Phase 1/1b Clinical Trial of IMU-856 in the Peer Reviewed Journal, The Lancet Gastroenterology & Hepatology | Issuer: Immunic AG
/ Key word(s): Scientific publication
Immunic Announces Publication of Data From Phase 1/1b Clinical Trial of IMU-856 in the Peer Reviewed Journal, The Lancet... ► Artikel lesen | |
| PHIO PHARMACEUTICALS | 2,380 | 0,00 % | Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Announces Completion of Enrollment in Second Cohort in Phase 1b Dose-Escalating Clinical Study | --Six sites across the U.S. are now engaged in Phase1b study Marlborough, Massachusetts--(Newsfile Corp. - November 19, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology... ► Artikel lesen | |
| ADAPTIVE BIOTECHNOLOGIES | 4,188 | -0,26 % | Adaptive Biotechnologies Corp reports results for the quarter ended September 30 - Earnings Summary |
Das Unternehmen BRII BIOSCIENCES LTD kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -0,83 % bei einem Aktienkurs von 0,119 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BRII BIOSCIENCES LTD finden Sie auf Wallstreet Online.
